The PMPRB has extended the deadline for comments on the revised draft Guidelines to August 4, 2020.
See here for further details on the change. Please also see our June 23, 2020 article for a summary of notable changes in the revised draft Guidelines.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency seeks input on HTA methods guide and also announces new coalition to improve medication use
HTA Methods Guide – On November 28, 2024, Canada’s Drug Agency (CDA) launched a consultation on its first-ever methods guide.Read More -
2023-2024 Pan-Canadian Pharmaceutical Alliance impact report
On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.Read More -
PMPRB releases new Draft Guidelines for comment
Following its Phase 2 Consultations, on December 19, 2025, the Patented Medicine Prices Review Board released its new Draft Guidelines and accompanying Overview.Read More